Yan Xu

2.2k total citations
111 papers, 1.1k citations indexed

About

Yan Xu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Yan Xu has authored 111 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Hematology, 51 papers in Molecular Biology and 40 papers in Oncology. Recurrent topics in Yan Xu's work include Multiple Myeloma Research and Treatments (66 papers), Protein Degradation and Inhibitors (26 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Yan Xu is often cited by papers focused on Multiple Myeloma Research and Treatments (66 papers), Protein Degradation and Inhibitors (26 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Yan Xu collaborates with scholars based in China, United States and Spain. Yan Xu's co-authors include Lugui Qiu, Mu Hao, Shuhui Deng, Dehui Zou, Gang An, Weiwei Sui, Chikao Morimoto, Junichi Kameoka, Martin Hegen and Toshiaki Tanaka and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yan Xu

93 papers receiving 1.1k citations

Peers

Yan Xu
Nathalie Belhacène France
Simone Boehrer Germany
Michael Wanzel Germany
S P Treon United States
Makiko Kawaguchi Japan
Stephanie Lefèvre Germany
Ebrahim Sakhinia Iran
Christine Huard United States
Zhihong Fang China
P. J. Quesenberry United States
Nathalie Belhacène France
Yan Xu
Citations per year, relative to Yan Xu Yan Xu (= 1×) peers Nathalie Belhacène

Countries citing papers authored by Yan Xu

Since Specialization
Citations

This map shows the geographic impact of Yan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Xu more than expected).

Fields of papers citing papers by Yan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Xu. The network helps show where Yan Xu may publish in the future.

Co-authorship network of co-authors of Yan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Xu. A scholar is included among the top collaborators of Yan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Xu. Yan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yan, Yuting, Tingyu Wang, Tengteng Yu, et al.. (2025). Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study. Clinical Cancer Research. 31(10). 1856–1864. 1 indexed citations
2.
3.
Liu, Wei, Xiaojuan Wang, Chunyang Wang, et al.. (2024). Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Journal for ImmunoTherapy of Cancer. 12(3). e008450–e008450. 9 indexed citations
4.
Xiong, Yu, Tengteng Yu, Shuaishuai Zhang, et al.. (2024). Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report. Journal for ImmunoTherapy of Cancer. 12(11). e010080–e010080. 2 indexed citations
5.
6.
Liu, Jiahui, Yan Xu, Weiwei Sui, et al.. (2024). Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. American Journal of Hematology. 99(4). 523–533. 7 indexed citations
7.
Li, Lingna, Yuting Yan, Yan Xu, et al.. (2023). Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. Cancer Research Communications. 3(9). 1770–1780. 4 indexed citations
8.
Yao, Yao, Mehmet Samur, Eugenio Morelli, et al.. (2023). CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 141(23). 2841–2852. 17 indexed citations
9.
10.
Encinas, Jessica, Yao Yao, Yan Xu, et al.. (2022). Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Advances. 7(1). 9–19. 17 indexed citations
11.
Sun, Hao, Tingyu Wang, Zhen Yu, et al.. (2022). Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia. Journal of Translational Medicine. 20(1). 576–576. 10 indexed citations
12.
Qiu, Lan, et al.. (2022). Blockade of PD-1/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease. International Immunopharmacology. 110. 109051–109051. 8 indexed citations
13.
14.
Perini, Tommaso, Raphaël Szalat, Mariateresa Fulciniti, et al.. (2017). Bone Marrow Microenvironment Induces Genomic Instability and Enables Clonal Evolution in Multiple Myeloma. Blood. 130. 4408. 1 indexed citations
15.
Li, Heng, Shuhua Yi, Wenjie Xiong, et al.. (2017). Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.. SHILAP Revista de lepidopterología. 130(2). 135–142. 5 indexed citations
16.
17.
Hao, Mu, Meirong Zang, Yan Xu, et al.. (2015). Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis. Blood. 126(23). 4186–4186. 2 indexed citations
18.
Feng, Xiaoyan, Shuhui Deng, Gang An, et al.. (2015). [Clinical characteristics and survival of newly diagnosed multiple myeloma patients under 40 years old from single center and literature review].. PubMed. 36(11). 933–6. 1 indexed citations
19.
Li, Zengjun, Yan Xu, Gang An, et al.. (2015). [The characteristics of 62 cases of CD20-positive multiple myeloma].. PubMed Central. 36(1). 44–8. 3 indexed citations
20.
Li, Fei, Mu Hao, Xiaoyan Feng, et al.. (2015). Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leukemia Research. 39(7). 793–799. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nathalie Belhacène Breakdown of academic impact, for papers by Simone Boehrer Breakdown of academic impact, for papers by Michael Wanzel Breakdown of academic impact, for papers by S P Treon Breakdown of academic impact, for papers by Makiko Kawaguchi Breakdown of academic impact, for papers by Stephanie Lefèvre Breakdown of academic impact, for papers by Ebrahim Sakhinia Breakdown of academic impact, for papers by Christine Huard Breakdown of academic impact, for papers by Zhihong Fang Breakdown of academic impact, for papers by P. J. Quesenberry
Rankless by CCL
2026